G-PLUS: Guselkumab vs Placebo in Palmoplantar Psoriasis

• Research type

  Research Study

• Full title

  A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis

• IRAS ID

  264950

• Contact name

  Nick Hodges

• Contact email

  GCOUKSubmissions@its.jnj.com

• Sponsor organisation

  Janssen Cilag International NV

• Eudract number

  2018-003206-58

• Clinicaltrials.gov Identifier

  41953, CPMS ID Number

• Duration of Study in the UK

  2 years, 0 months, 27 days

• Research summary

  This is a research study in 105 adults with Palmoplantar non-pustular Psoriasis (PPP). Psoriasis is a chronic inflammatory disease affecting between 1-3% of the population worldwide. PPP is a specific type of psoriasis and affects about 12% of Psoriasis patients in total. It is characterised by lesions on the palms of the hands and soles of the feet. PPP is associated with a great impairment in quality of life and the use of biologic treatments has proven to be effective. However there remains an unmet need for effective treatment of PPP confirmed by randomised controlled trials.

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  19/LO/1035

• Date of REC Opinion

  29 Jul 2019

• REC opinion

  Further Information Favourable Opinion